HBOT for PTSD and Mental Health: What the Research Shows

The short answer: The signal is real but unsettled. A 2024 sham-controlled trial in combat veterans reported average PTSD scores falling from 42.6 to 25.8 (CAPS-5, p<0.001) while the sham group actually worsened, backed by brain-imaging changes in earlier work. But independent US military trials found HBOT no better than a low-pressure sham, essentially all positive data come from one Israeli research group, and PTSD is not an FDA-cleared or UHMS-approved use of HBOT. Treat it as promising, investigational, and unproven.

Few HBOT topics carry more emotional weight than PTSD. The people searching for it are often veterans, trauma survivors, or the families around them, and many have already cycled through therapy and medication without the relief they hoped for. That makes the subject easy to exploit and hard to write about honestly, because the wish for something new is so strong. The temptation is to either promise a breakthrough or dismiss the idea outright. Neither is accurate.

The truth sits in an uncomfortable middle. There is a genuinely striking recent trial suggesting hyperbaric oxygen can reduce PTSD symptoms and change the brain in measurable ways. There is also a set of rigorous military trials that failed to separate HBOT from placebo, and a real problem that almost all the encouraging data come from a single group of researchers. Holding both of those facts at once is the only defensible way to cover this.

Disclosure: Superhuman Chambers manufactures and sells hyperbaric chambers for wellness operators and home use. This article summarizes published research and is not medical advice, diagnosis, or a treatment recommendation. HBOT is not FDA-cleared or guideline-endorsed for PTSD or any psychiatric condition; that use is investigational. PTSD is a serious medical condition that belongs under the care of a qualified mental-health professional.

Why HBOT is being studied for PTSD

The rationale starts with what PTSD looks like in the brain, not just in behavior. Chronic trauma is associated with an overactive amygdala (the threat-detection center), reduced activity and blood flow in the prefrontal cortex and hippocampus, and weakened connectivity between the emotional and regulatory parts of the brain. That pattern is thought to make traumatic memories hard to file away as “past.” The question researchers are asking is whether these are purely functional patterns or whether some of the underlying tissue is metabolically underperforming in a way that could be nudged.

Modern HBOT protocols lean on what researchers call the hyperoxic-hypoxic paradox: intermittent swings in tissue oxygen can trigger the same repair signaling (HIF-1, VEGF) that low oxygen would, driving angiogenesis, mitochondrial support, neural stem-cell activity, and a calmer neuroinflammatory state. The proposed downstream effects are better regional blood flow and reactivation of “hibernating” brain regions, which is exactly what the Israeli trials report seeing on functional MRI and diffusion imaging. This is a coherent, imaging-supported hypothesis. It is not the same as a proven treatment, and the leap from an imaging change to durable relief is precisely what remains unconfirmed.

The strongest evidence: the sham-controlled trials

The most impressive results come from a research group at the Sagol Center, Shamir Medical Center in Israel. Their work is the reason this topic is taken seriously at all, and it deserves a fair reading before the caveats.

Taken on their own, these are genuinely encouraging. A sham-controlled design is the right way to test HBOT, a CAPS-5 drop of that size is clinically meaningful, and the fact that the sham group did not improve (and even worsened) argues against a pure placebo explanation in that particular trial. The imaging correlates add mechanistic weight: something measurable is changing in brain structure and function, not just on a questionnaire.

There is a caveat threaded through the strength, though. The 2022, 2024, and 2025 papers are all from the same group and, in the 2025 case, the same 56 patients re-analyzed. Consistent findings from one lab are a starting point, not independent confirmation. For that, you have to look at who else has run the experiment, and what they found.

The counterweight: the trials that came back null

This is the part that responsible coverage cannot skip. When the US military studied HBOT for post-concussion symptoms and PTSD, the results were far less flattering, and they expose a methodological problem that still hangs over the whole field.

The clearest example is the HOPPS trial (Miller, Weaver et al., 2015, JAMA Internal Medicine, n=72). Service members with persistent post-concussion symptoms improved on PTSD checklist scores after HBOT, but they improved just as much in the low-pressure sham group, and both beat routine care. Earlier US Air Force and dose-comparison trials (Wolf 2012; Cifu 2014) landed in the same place: symptom scores went up in both the HBOT and the sham arms, so the oxygen could not be credited with the benefit. The BIMA study told a similar, ambiguous story.

The reason this matters is the sham problem at the heart of HBOT research. You cannot give someone a convincing “fake” chamber session; even a low-pressure, room-air sham involves lying in a chamber, feeling pressure in the ears, and expecting to get better. If both groups improve, it is very hard to prove the oxygen did anything. Proponents argue the low-pressure sham is itself biologically active rather than inert, which is plausible but unproven, and it cuts both ways: it is equally an argument that the effect is participation and expectation, not pressure and oxygen.

One more honesty point belongs here. A 2024 systematic review reported a dose-response relationship for HBOT in PTSD, but it was co-authored by a long-standing HBOT advocate and concluded the therapy “should be recommended,” so it reads as advocacy, not neutral synthesis. That same review flagged a reversible but sometimes severe worsening of emotional symptoms in 30–39% of subjects at the highest doses. In a population already carrying trauma, a transient mood exacerbation is not a footnote; it is a reason for medical supervision.

What is approved: nothing, yet

The regulatory picture is unambiguous, and it is the fastest way to calibrate expectations.

• The FDA has not cleared HBOT for PTSD or any psychiatric condition. Its cleared indications are physical conditions such as decompression sickness, carbon-monoxide poisoning, non-healing wounds, and radiation injury. PTSD and TBI uses are off-label.
• The UHMS does not list PTSD among its accepted indications, and neither does the European consensus.
• The VA and Defense Health Agency remain skeptical. Their evidence reviews conclude the data do not support HBOT for TBI, and that in the controlled military trials, PTSD improvement was not superior to sham.

In short, no major body (FDA, UHMS, VA/DoD, or the American Psychiatric Association) endorses HBOT for PTSD. It is an active research question, not a standard of care.

Limitations and honest caveats

The guardrails on this topic are unusually important because the audience is vulnerable:

• Small trials. The strongest positive RCT enrolled 56 completers. There is no large, multi-site confirmatory trial of the 2.0 ATA protocol.
• Single-group dominance. The compelling sham-controlled and imaging results come almost entirely from one Israeli center, with no independent replication yet. The independent US trials were null or ambiguous.
• The sham problem is unresolved. Because low-pressure sham sessions themselves produce improvement, separating oxygen from expectation remains genuinely difficult.
• Narrow population. The best trial studied only men aged 25–60 and excluded TBI, yet real-world PTSD often coexists with brain injury. Results may not transfer to women, older adults, or PTSD-plus-TBI.
• Short follow-up. Positive durability data extend only about three months. Long-term effects are unknown.
• A real safety signal. Transient emotional worsening in a meaningful minority at high doses means this is not a self-directed wellness experiment. See our side effects and contraindications guide.

What this means for wellness operators

For operators, the line is bright and worth respecting: do not market HBOT as a PTSD or mental-health treatment. It is not FDA-cleared, it is not guideline-endorsed, the strongest evidence lacks independent replication, and the population is vulnerable enough that a careless claim is both an ethical and a legal hazard. Promising trauma relief from a chamber is exactly the kind of overreach that damages the credibility of the entire hyperbaric field. The chamber itself remains legitimate equipment for the recovery and cognitive-support work it is actually suited to, and operators weighing chambers from $15,000 should let those better-supported uses, not a PTSD claim, drive the purchase.

The defensible posture is to describe PTSD as an area of active, legitimate research with encouraging early trials and real unanswered questions, and to route anyone dealing with trauma toward qualified mental-health care rather than a session package. Where HBOT belongs in a wellness setting is the recovery, sleep, and cognitive-support conversations, handled with the same honesty, and even there the claims should stay tied to what the evidence actually shows. For adjacent, better-characterized topics, see our guides on HBOT for cognitive function and brain fog, HBOT for concussion recovery, and whether HBOT can improve sleep. To talk through how to position an evidence-heavy hyperbaric program responsibly, you can learn more about Superhuman or contact the team.

References

1. Doenyas-Barak K, Kutz I, Lang E, Assouline A, Hadanny A, Aberg KC, Levi G, Beberashvili I, Mayo A, Efrati S. Hyperbaric oxygen therapy for veterans with combat-associated posttraumatic stress disorder: a randomized, sham-controlled clinical trial. J Clin Psychiatry. 2024. https://pubmed.ncbi.nlm.nih.gov/39566051/
2. Doenyas-Barak K, Catalogna M, Kutz I, Levi G, Hadanny A, Tal S, et al. Hyperbaric oxygen therapy improves symptoms, brain’s microstructure and functionality in veterans with treatment-resistant PTSD: a prospective, randomized, controlled trial. PLoS One. 2022;17(2):e0264161. https://doi.org/10.1371/journal.pone.0264161
3. Danan D, Grosskopf Y, Mayo A, Efrati S, et al. Hyperbaric oxygen therapy for PTSD: threshold effect for sustained symptom improvement in a biologically based treatment. Brain and Behavior. 2025;15(8):e70757. https://onlinelibrary.wiley.com/doi/full/10.1002/brb3.70757
4. Miller RS, Weaver LK, Bahraini N, Churchill S, Price RC, Skiba V, et al. Effects of hyperbaric oxygen on symptoms and quality of life among service members with persistent postconcussion symptoms (HOPPS): a randomized clinical trial. JAMA Intern Med. 2015;175(1):43–52. https://pubmed.ncbi.nlm.nih.gov/25401463/
5. Andrews SR, Harch PG. Systematic review and dosage analysis: hyperbaric oxygen therapy efficacy in the treatment of posttraumatic stress disorder. Front Neurol. 2024;15:1360311. https://doi.org/10.3389/fneur.2024.1360311
6. Doenyas-Barak K, et al. The use of hyperbaric oxygen therapy for veterans with PTSD: a narrative review. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10630921/
7. Defense Health Agency. Information paper: hyperbaric oxygen therapy and traumatic brain injury. 2025. https://health.mil/
8. U.S. Food and Drug Administration. Hyperbaric oxygen therapy: get the facts. FDA Consumer Update. https://www.fda.gov/consumers/consumer-updates/hyperbaric-oxygen-therapy-get-facts